Aarti Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0LRU01027
  • NSEID: AARTIPHARM
  • BSEID: 543748
INR
721.55
-1.45 (-0.2%)
BSENSE

Dec 05

BSE+NSE Vol: 1.51 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1003784,
    "name": "Aarti Pharma",
    "stock_name": "Aarti Pharma",
    "full_name": "Aarti Pharmalabs Ltd",
    "name_url": "stocks-analysis/aarti-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "721.55",
    "chg": -1.45,
    "chgp": "-0.2%",
    "dir": -1,
    "prev_price": "723.00",
    "mcapval": "6,526.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543748,
    "symbol": "AARTIPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0LRU01027",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.51 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aarti-pharma-1003784-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Aarti Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aarti-pharma-technically-bullish-or-bearish-3745746",
        "imagepath": "",
        "date": "2025-12-04 08:51:19",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Technical Trend Shift</strong></p>\n<p>As of 03 Dec 2025, Aarti Pharma's overall technical trend transitioned from bearish to mildly bearish. This subtle change reflects a market environment where downward pressures have somewhat eased, but a clear bullish reversal remains elusive. The mildly bearish classification suggests that while the stock is not in a strong downtrend, it has yet to establish convincing upward momentum.</p>\n<p><strong>Key Technical Indicators Breakdown</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish stance on the weekly timeframe and a mildly bearish position monthly. This divergence implies that short-term momentum is weaker, and the longer-term trend has not fully recovered.</p>\n..."
      },
      {
        "title": "Aarti Pharmalabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-technical-momentum-shifts-amid-mixed-indicator-signals-3745549",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AartiPharmalabs_technicaldot_3745549.png",
        "date": "2025-12-04 08:12:41",
        "description": "Aarti Pharmalabs has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators across multiple timeframes. The pharmaceutical and biotechnology company’s stock price movements and technical signals suggest a period of cautious market assessment as investors digest recent evaluation adjustments."
      },
      {
        "title": "Aarti Pharmalabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-technical-momentum-shifts-amid-mixed-indicator-signals-3743064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AartiPharmalabs_technicaldot_3743064.png",
        "date": "2025-12-03 08:09:19",
        "description": "Aarti Pharmalabs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced notable shifts in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Recent market data reveals a nuanced picture of price action and indicator behaviour, suggesting evolving investor sentiment and potential implications for the stock’s near-term trajectory."
      },
      {
        "title": "Aarti Pharmalabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-technical-momentum-shifts-amid-mixed-indicator-signals-3740444",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AartiPharmalabs_technicaldot_3740444.png",
        "date": "2025-12-02 08:12:53",
        "description": "Aarti Pharmalabs, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition from a predominantly bearish outlook to a mildly bearish stance, underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages."
      },
      {
        "title": "How has been the historical performance of Aarti Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aarti-pharma-3739414",
        "imagepath": "",
        "date": "2025-12-01 23:40:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Since fiscal year ending March 2022, Aarti Pharma’s net sales have shown robust expansion, rising from ₹1,199.94 crores to ₹2,115.07 crores by March 2025. This represents a compound growth rate exceeding 25% annually, reflecting strong market demand and operational scaling. The operating profit margin (excluding other income) has improved from 17.25% in 2022 to 21.95% in 2025, signalling enhanced operational efficiency and cost management.</p>\n<p>Profit after tax (PAT) has also followed an encouraging path, increasing from ₹122.25 crores in 2022 to ₹272.40 crores in 2025. Correspondingly, the PAT margin rose from 10.19% to 12.88%, underscoring the company’s ability to convert sales growth into bottom-line gains. Earnings per share (EPS) have mirrored..."
      },
      {
        "title": "Aarti Pharmalabs: Analytical Revisions Reflect Mixed Signals Amidst Financial and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-pharmalabs-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3732679",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiPharmalabs_mojoScore_3732679.png",
        "date": "2025-11-27 08:17:55",
        "description": "Aarti Pharmalabs has undergone a revision in its market assessment following a detailed evaluation of its quality, valuation, financial trends, and technical indicators. The pharmaceutical company’s recent financial disclosures and market behaviour have prompted a nuanced analytical perspective, highlighting both challenges and areas of relative strength amid a complex industry backdrop."
      },
      {
        "title": "Aarti Pharmalabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-technical-momentum-shifts-amid-bearish-signals-3732608",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiPharmalabs_technicaldot_3732608.png",
        "date": "2025-11-27 08:08:55",
        "description": "Aarti Pharmalabs has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish indicators across multiple timeframes. The stock's recent price action and technical signals suggest a nuanced market assessment, with mixed signals from key momentum and trend-following indicators."
      },
      {
        "title": "Aarti Pharmalabs Forms Death Cross Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-forms-death-cross-signalling-potential-bearish-trend-3731886",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiPharmalabs_dealthcross_3731886.png",
        "date": "2025-11-26 18:01:37",
        "description": "Aarti Pharmalabs, a player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and may indicate weakening momentum in the stock’s price over the longer term."
      },
      {
        "title": "Aarti Pharmalabs Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-pharmalabs-technical-momentum-shifts-amid-mixed-indicator-signals-3717121",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiPharmalabs_technicaldot_3717121.png",
        "date": "2025-11-20 08:09:10",
        "description": "Aarti Pharmalabs, a key player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments highlight a transition from a sideways trend to a mildly bearish stance, with technical indicators presenting a nuanced picture for investors and market watchers alike."
      }
    ],
    "total": 251,
    "sid": "1003784",
    "stock_news_url": "https://www.marketsmojo.com/news/aarti-pharmalabs-1003784"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "17-Nov-2025",
      "details": "Transcript of Q2 FY 26 Earnings Conference Call.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "11-Nov-2025",
      "details": "Recording of the Earnings Conference call for Q2 FY 26",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "11-Nov-2025",
      "details": "Investor Presentation for Q2 FY 26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Pharmalabs Ltd has declared <strong>50%</strong> dividend, ex-date: 15 Sep 25",
          "dt": "2025-09-15",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

Is Aarti Pharma technically bullish or bearish?

2025-12-04 08:51:19

Recent Technical Trend Shift

As of 03 Dec 2025, Aarti Pharma's overall technical trend transitioned from bearish to mildly bearish. This subtle change reflects a market environment where downward pressures have somewhat eased, but a clear bullish reversal remains elusive. The mildly bearish classification suggests that while the stock is not in a strong downtrend, it has yet to establish convincing upward momentum.

Key Technical Indicators Breakdown

Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish stance on the weekly timeframe and a mildly bearish position monthly. This divergence implies that short-term momentum is weaker, and the longer-term trend has not fully recovered.

...

Read More

How has been the historical performance of Aarti Pharma?

2025-12-01 23:40:54

Revenue and Profit Growth

Since fiscal year ending March 2022, Aarti Pharma’s net sales have shown robust expansion, rising from ₹1,199.94 crores to ₹2,115.07 crores by March 2025. This represents a compound growth rate exceeding 25% annually, reflecting strong market demand and operational scaling. The operating profit margin (excluding other income) has improved from 17.25% in 2022 to 21.95% in 2025, signalling enhanced operational efficiency and cost management.

Profit after tax (PAT) has also followed an encouraging path, increasing from ₹122.25 crores in 2022 to ₹272.40 crores in 2025. Correspondingly, the PAT margin rose from 10.19% to 12.88%, underscoring the company’s ability to convert sales growth into bottom-line gains. Earnings per share (EPS) have mirrored...

Read More
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

17-Nov-2025 | Source : BSE

Transcript of Q2 FY 26 Earnings Conference Call.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

11-Nov-2025 | Source : BSE

Recording of the Earnings Conference call for Q2 FY 26

Announcement under Regulation 30 (LODR)-Investor Presentation

11-Nov-2025 | Source : BSE

Investor Presentation for Q2 FY 26

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Aarti Pharmalabs Ltd has declared 50% dividend, ex-date: 15 Sep 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available